Brief: Eloxx Pharmaceuticals Reports First Quarter 2023 Financial And Operating Results And Provides Business Update
15/05/2023 22:45
Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL
AND
OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
* ELOXX PHARMACEUTICALS INC - QTRLY NET LOSS OF $2.88 PER
SHARE
* ELOXX PHARMACEUTICALS INC - AS OF MARCH 31, 2023, HAD
UNRESTRICTED CASH AND CASH EQUIVALENTS OF $4.9 MILLION
* ELOXX PHARMACEUTICALS - EXPECTS CURRENT CASH POSITION WILL
BE
SUFFICIENT TO FUND OPERATIONS INTO Q3 2023
Source text for Eikon: ID:nGNX4QT8yR
Further company coverage: ELOX.O
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome